Measurement and analysis of patient attenuation correction factor during radioiodine therapy
- 9 April 2015
- journal article
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 165 (1) , 448-451
Abstract
The calculated dose rate from the radioiodine therapy patient should normally include a factor accounting for the attenuation and scatter of patient body tissues. The attenuation factor is currently neglected, and not applied in operational radiation protection. Realistic estimation of radiation dose rate levels from radioiodine therapy patients when properly performed will reduce operational cost and optimise institutional radiation protection practice. In this work, the existence of a patient body tissue attenuation factor is verified by comparing the dose rates measured from the radioiodine capsules immediately before administration with those measured from the patient immediately after administration. The correlation between the factors suspected to influence the patient body tissue attenuation and the measured dose rates from the patient normalised per unit activity is statistically analysed. The calculated attenuation correction factor based on authors’ measurements was (0.55±0.17). The measured dose rate per unit of radioactivity from the patient showed a negative correlation with their body mass index.Keywords
This publication has 13 references indexed in Scilit:
- Comparison of Measured and Calculated Dose Rates Near Nuclear Medicine PatientsHealth Physics, 2013
- Assessment of radioiodine clearance in patients with differentiated thyroid cancerRadiation Protection Dosimetry, 2012
- EXPOSURE RATE CONSTANTS AND LEAD SHIELDING VALUES FOR OVER 1,100 RADIONUCLIDESHealth Physics, 2012
- Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 CasesJournal of Nuclear Medicine, 2011
- Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131Nuclear Medicine and Molecular Imaging, 2010
- Use of a Voxel Phantom as a Source and a Second Voxel Phantom as a Target to Calculate Effective Doses in Individuals Exposed to Patients Treated with 131IJournal of Nuclear Medicine Technology, 2009
- Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidismEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- CORRELATION BETWEEN EXTERNAL EXPOSURE AND ACTIVITY IN PATIENTS UNDERGOING 131I THYROID CANCER THERAPYHealth Physics, 2008
- CORRECTION FACTORS FOR MORE ACCURATE ESTIMATES OF EXPOSURE RATES NEAR RADIOACTIVE PATIENTS: EXPERIMENTAL, POINT, AND LINE SOURCE MODELSHealth Physics, 2007
- Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosisNuclear Medicine Communications, 1993